TNDM:NSD-Tandem Diabetes Care Inc.

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 64.41

Change

+0.71 (+1.11)%

Market Cap

USD 0.07B

Volume

0.74M

Analyst Target

USD 79.23
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tandem Diabetes Care Inc is a medical device company engaged in the designing, development and commercialization of products for people with insulin-dependent diabetes. The Company's flagship product is the t:slim Insulin Delivery System.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.45 (-0.32%)

USD 51.34B
ALGN Align Technology Inc

+7.96 (+2.49%)

USD 24.03B
BRKR Bruker Corporation

+1.46 (+1.58%)

USD 12.93B
PODD Insulet Corporation

+3.66 (+2.21%)

USD 11.49B
SWAV Shockwave Medical Inc

+6.54 (+2.07%)

USD 10.25B
MASI Masimo Corporation

+3.83 (+2.72%)

USD 7.14B
AXNX Axonics Modulation Technologie..

-0.06 (-0.09%)

USD 3.52B
IRTC iRhythm Technologies Inc

+0.76 (+0.66%)

USD 3.36B
QDEL Quidel Corporation

+1.26 (+2.68%)

USD 3.14B
LIVN LivaNova PLC

+1.48 (+2.72%)

USD 3.02B

ETFs Containing TNDM

SLIM 0.00 % 0.50 %

N/A

N/A
SSLY Syntax Stratified SmallCa.. 0.00 % 0.00 %

+1.10 (+2.51%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.63% 90% A- 92% A
Dividend Return N/A N/A N/A N/A F
Total Return 69.63% 90% A- 92% A
Trailing 12 Months  
Capital Gain 148.78% 95% A 98% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 148.78% 95% A 98% N/A
Trailing 5 Years  
Capital Gain -51.82% 39% F 24% F
Dividend Return N/A N/A N/A N/A F
Total Return -51.82% 39% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 192.16% 98% N/A 95% A
Dividend Return 192.16% 98% N/A 94% A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 493.77% 2% F 6% D-
Risk Adjusted Return 38.92% 59% D- 64% D
Market Capitalization 0.07B 94% A 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 30.88 6% 4%
Price / Cash Flow Ratio 0.00 10% 21%
Price/Free Cash Flow Ratio 0.00 10% 14%
Management Effectiveness  
Return on Equity -170.03% 22% 6%
Return on Invested Capital -2,139,549,376.80% 22% 13%
Return on Assets -13.96% 52% 24%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.